Accelerating Medical Treatments for Serious Mental Illness

The order directs federal agencies to accelerate research, review, and patient access for psychedelic drugs (including ibogaine compounds) to treat serious mental illnesses by prioritizing FDA review and creating pathways under the Right to Try Act. It instructs the FDA to issue National Priority Vouchers for qualifying Breakthrough Therapy psychedelic drugs and directs the FDA and DEA to establish handling authorizations and access pathways for eligible patients and treating physicians.